2 results
Approved WMOCompleted
1) To compare pembrolizumab plus olaparib to abiraterone acetate or enzalutamide with respect to overall survival (OS)2) To compare pembrolizumab plus olaparib to abiraterone acetate or enzalutamide with respect to radiographic progression-free…
Approved WMOSuspended
The aim of this study is to identify whether it is possible to safely discontinue treatment in stable RRMS patients who have shown no evidence of active inflammation in the years prior to inclusion in terms of the return of inflammatory disease…